ODN 2395

ODN 2395 (40 μg/per mouse; i.p.; 2 doses (5th and 6th weeks post-infection)) increases serum HDL-C and IgG1 levels, and up-regulates liver TCR, ICOS, and Bax gene expression in normal nutritional status mice infected with Leishmania donovani, but does not reduce parasite loads or alter key immune cell or cytokine profiles^[1].
ODN 2395 (40 μg/per mouse; i.p.; 2 doses (5th and 6th weeks post-infection)) significantly reduces spleen parasite load, enhances Th1-type immune responses, increases serum HDL-C, and elevates IgG1 antibody levels in obesity mice infected with Leishmania donovani^[1].
ODN 2395 (40 μg/per mouse; i.p.; 2 doses (5th and 6th weeks post-infection)) significantly reduces spleen parasite load, up-regulates key spleen immune activation genes, reduces inhibitory cytokine levels, increases CD3⁺ T cell proportions, and down-regulates most measured liver immune and apoptosis-related genes in undernutrition mice infected with Leishmania donovani^[1].
ODN 2395 (50 μg/mouse; i.n.; single dose; 1 day pre-infection) confers 55% survival in HSV-1-infected BALB/c mice, significantly reduces brain viral load and pro-inflammatory cytokine production, and extends mean life expectancy to 17.4 days^[2].
ODN 2395 (50 μg/mouse; i.n.; single dose; 3 days post-infection) results in 0% survival in HSV-1-infected BALB/c mice, does not reduce whole-brain viral load, and increases viral load in the olfactory bulb at day 5 post-infection^[2].